Advertisement

Topics

Haematological cancer: Where are we now with the treatment of multiple myeloma?

15:30 EDT 13 Jun 2017 | Nature Publishing

The current standard-of-care therapy for patients with multiple myeloma is autologous stem-cell transplantation; however, whether this approach should be enhanced or displaced by triplet combination therapy is the subject of ongoing debate. We discuss the latest trial that has attempted to address this question and the impact of transplantation and triplet therapy assessment and surrogate end points in future trial design.

Original Article: Haematological cancer: Where are we now with the treatment of multiple myeloma?

NEXT ARTICLE

More From BioPortfolio on "Haematological cancer: Where are we now with the treatment of multiple myeloma?"

Quick Search
Advertisement
 

Relevant Topic

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...